Atommap

Executive Summary

Atommap is a San Francisco-based computational drug discovery company founded in 2020 that leverages AI and molecular dynamics simulations to design novel therapeutics targeting biomolecular motion. The company's platform focuses on generating molecular glues and degraders to address challenging drug targets, with the goal of reprogramming protein function. Despite being in an early stage with no disclosed funding or pipeline, Atommap operates in the high-growth AI-driven drug discovery space, which has seen significant interest from investors and pharmaceutical partners. The company's unique approach to targeting protein dynamics could differentiate it in the competitive landscape, but its lack of publicly available milestones or partnerships limits visibility. If successful, Atommap could address undruggable targets, but execution risks remain high given the technical challenges and capital requirements of drug discovery.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Announcement60% success
• Q4 2026Research Partnership with Major Pharma40% success
• Q2 2026Peer-Reviewed Publication of Platform Validation50% success